m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05665
 [1]
m6A modification FGD5-AS1 FGD5-AS1 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA FGD5-AS1 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target FGD5 antisense RNA 1 (FGD5-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator FGD5 antisense RNA 1 (FGD5-AS1) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3 could upregulate FGD5 antisense RNA 1 (FGD5-AS1) expression via N6-methyladenosine (m6A) modification.research has shed light on the involvement of the METTL3/FGD5-AS1 axis in the development of PTX resistance in EC
Responsed Disease Endometrial cancer ICD-11: 2C76
 Disease Info 
Responsed Drug paclitaxel (PTX)
 Drug Info 
Cell Process Cell proliferation
Cell migration
In-vitro Model
 Ishikawa Endometrial adenocarcinoma Homo sapiens CVCL_2529
HHUA Endometrial adenocarcinoma Homo sapiens CVCL_3866
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C76: Endometrial cancer 18 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Dostarlimab Approved [2]
External Link
TTD: DGQU43
 Compound Name Lurbinectedin Phase 3 [3]
Synonyms
UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B
    Click to Show/Hide
External Link
CID: 57327016
TTD: D0V6OA
DrugBank: DB12674
 Compound Name Mirvetuximab soravtansine Approved [3]
Synonyms
ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489
    Click to Show/Hide
External Link
CID: 91810695
TTD: D0RP2W
 Compound Name AL3818 Phase 1/2 [3]
Synonyms
Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
    Click to Show/Hide
External Link
CID: 25017411
TTD: D0G2CG
DrugBank: DB11885
 Compound Name TKI258 Phase 3 [4]
Synonyms
Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
    Click to Show/Hide
External Link
CID: 135611162
TTD: D07OZR
 Compound Name DKN-01 Phase 2 [3]
External Link
TTD: DMF73Z
 Compound Name FP-1039 Phase 2 [5]
Synonyms
FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
    Click to Show/Hide
External Link
TTD: D0U2DO
 Compound Name XBIO-101 Phase 2 [3]
Synonyms
sodium cridanimod; cridanimod; 38609-97-1; 9-Oxo-10(9H)-acridineacetic acid; 10-Carboxymethyl-9-acridanone; N-(Carboxymethyl)acridone; (9-oxoacridin-10(9H)-yl)acetic acid; 10(9H)-ACRIDINEACETIC ACID, 9-OXO-; Cridanimod [INN]; 2-(9-oxoacridin-10(9H)-yl)acetic acid; (9-Oxo-9H-acridin-10-yl)-acetic acid; UNII-X91E9EME19; 10-Carboxymeth-9-acridanone; Cycloferon; BRN 0227508; 9-Oxo-10-acridanacetic acid; X91E9EME19; C15H11NO3; Cridanimod (INN); 2-(9-oxoacridin-10-yl)acetic acid; 10(9H)-Acridineaceticacid, 9-oxo-; (9-Oxo-10(9H)-acrid
    Click to Show/Hide
External Link
CID: 38072
TTD: D0OS6P
DrugBank: DB13674
 Compound Name PF-04691502 Phase 2 [6]
Synonyms
1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
    Click to Show/Hide
External Link
CID: 25033539
TTD: D0N5JZ
DrugBank: DB11974
 Compound Name Folate binding protein vaccine Phase 2 [7]
External Link
TTD: D0M7YU
 Compound Name Virexxa Phase 2 [8]
External Link
TTD: D0J0EM
 Compound Name ONC201 Phase 2 [3]
Synonyms
Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
    Click to Show/Hide
External Link
CID: 73777259
TTD: D07XQS
DrugBank: DB14844
 Compound Name Folate binding protein-E39 Phase 1/2 [9]
External Link
TTD: D0OT3L
 Compound Name GALE-301 Phase 2 [10]
External Link
TTD: D02DEZ
 Compound Name COTI-2 Phase 1 [3]
Synonyms
UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
    Click to Show/Hide
External Link
CID: 91810660
TTD: D0G8CU
 Compound Name Anti-meso-CAR vector transduced T cells Phase 1 [11]
External Link
TTD: D0G4GY
 Compound Name GSK1059615 Discontinued in Phase 1 [12]
Synonyms
KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060
    Click to Show/Hide
External Link
CID: 23582824
TTD: D0L0ZC
DrugBank: DB11962
 Compound Name RU-46556 Terminated [13]
External Link
TTD: D0N4PC
References
Ref 1 METTL3-induced FGD5-AS1 contributes to the tumorigenesis and PD-1/PD-L1 checkpoint to enhance the resistance to paclitaxel of endometrial carcinoma. J Cell Mol Med. 2024 Mar;28(5):e17971. doi: 10.1111/jcmm.17971. Epub 2023 Sep 27.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015 Aug 1;121(15):2612-7.
Ref 5 ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health.
Ref 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7936).
Ref 7 Clinical pipeline report, company report or official report of Galena Biopharma.
Ref 8 ClinicalTrials.gov (NCT02064725) Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA. U.S. National Institutes of Health.
Ref 9 Clinical pipeline report, company report or official report of Galena biopharma.
Ref 10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035004)
Ref 11 ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Ref 12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028447)
Ref 13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003252)